APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 6736-6751

  Mongini, Patricia K A ^a,b   Inman, John K ^c   Han, Hanna ^a   Fattah, Rasem J ^c   Abramson, Steven B ^a,b   Attur, Mukundan ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; APRIL PROTEIN; B CELL ACTIVATION FACTOR OF THE TUMOR NECROSIS FACTOR FAMILY; B LYMPHOCYTE RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3DG; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 4; MEMBRANE PROTEIN; PROSTAGLANDIN E2; PROTEIN BR3; PROTEIN MCL 1; TRANSMEMBRANE ACTIVATOR AND CALCIUM MODULATOR AND CYCLOPHILIN LIGAND INTERACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CLONE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIVISION; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; DAUGHTER CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOBLAST; MITOCHONDRION; PRIORITY JOURNAL; PROGENY; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 33646894526     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.11.6736     Document Type: Article

References (118)

1. Dempsey, P. W., M. E. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
2. Fearon, D. T., and M. C. Carroll. 2000. Regulation of B lymphocyte responses to foreign and self antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18: 393-422.
3. Mongini, P. K. A., M. A. Vilensky, P. F. Highet, and J. K. Inman. 1997. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 149: 3782-3791.
4. Moore, P. A., O. Belvedere, A. Orr, K. Pieri, D. W. LaFleur, P. Feng, D. Soppet, M. Charters, R. Gentz, D. Parmelee, et al. 1999. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
5. Kalled, S. L., C. Ambrose, and Y. M Hsu. 2005. The biochemistry and biology of BAFF, APRIL and their receptors. Curr. Dir. Autoimmun. 8: 206-242.
6. Craxton, A., D. Magaletti, E. J. Ryan, and E. A. Clark. 2003. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101: 4464-4471.
7. Scapini, P., B. Nardelli, G. Nadali, F. Calzetti, G. Pizzolo, C. Montecucco, and M. A. Cassatella. 2003. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med. 197: 297-302.
8. + T cells in a TH2 response and in immunoglobulin E production. Science 270: 1845-1847.
9. Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan, and W. E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17: 701-738.
10. Gauchat, J. F., S. Henchoz, G. Mazzei, J. P. Aubry, T. Brunner, H. Blasey, P. Life, P., D. Talabot, L. Flores-Romo, J. Thompson, et al. 1993. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365: 340-343.
11. Weiss, D. L., and M. A. Brown. 2001. Regulation of IL-4 production in mast cells: a paradigm for cell-type-specific gene expression. Immunol. Rev. 179: 35-47.
12. Brandt, E., G. Woerly, A. B. Younes, S. Loiseau, and M. Capron. 2000. IL-4 production by human polymorphonuclear neutrophils. J. Leukocyte Biol. 68: 125-130.
13. Hodgkin, P. D., N. F. Go, J. E. Cupp, and M. Howard. 1991. Interleukin-4 enhances anti-IgM stimulation of B cells by improving cell viability and by increasing the sensitivity of B cells to the anti-IgM signal. Cell Immunol. 134: 14-30.
14. Mongini, P. K., P. F. Highet, and J. K. Inman. 1995. Human B cell activation. Effect of T cell cytokines on the physicochemical binding requirements for achieving cell cycle progression via the membrane IgM signaling pathway. J. Immunol. 155: 3385-4000.
15. Mongini, P. K. A., J. K. Inman, H. Han, S. L. Kalled, R. J. Fattah, and S. McCormick. 2005. Innate immunity and human B cell clonal expansion: Effects on the recirculating B2 subpopulation. J. Immunol. 175: 6143-6154.
16. Randen, I., O. J. Mellbye, O. Forre, and J. B. Natvig. 1995. The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand. J. Immunol. 41: 481-486.
17. Takemura, S., A. Braun, C. Crowson, P. J. Kurtin, R. H. Cofield, W. M. O'Fallon, J. J. Goronzy, and C. M. Weyand. 2001. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167; 1072-1080.
18. Stott, D. I., F. Hiepe, M. Hummel, G. Steinhauser, and C. Berek. 1998. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J. Clin. Invest. 102: 938-946.
19. Bahler, D. W., and S. H. Swerdlow. 1998. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as non-malignant antigen-selected expansions. Blood 91: 1864-1872.
20. Armengol, M. P., M. Juan, A. Lucas-Martin, M. T. Fernandez-Figueras, D. Jaraquemada, T. Gallart, and R. Pujol-Borrell. 2001. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am. J. Pathol. 159: 861-873.
21. Monteverde, A., M. Ballare, and S. Pileri. 1997. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin. Immunopath. 19: 99-110.
22. Silveira, P. A., J. Dombrowsky, E. Johnson, H. D. Chapman, D. Nemazee D, and D. V. Serreze. 2004. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J. Immunol. 172: 5086-5094.
23. Hussain, S., K. V. Salojin, and T. L. Delovitch. 2004. Hyperresponsiveness, resistance to B-cell receptor-dependent activation-induced cell death, and accumulation of hyperactivated B-cells in islets is associated with the onset of insulitis but not type 1 diabetes. Diabetes 53: 2003-2011.
24. Corcione, A., S. Casazza, E. Ferretti, D. Giunti, E. Zappia, A. Pistorio, C. Gambini, G. L. Mancardi, A. Uccelli, and V. Pistoia. 2004. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 101: 11064-11069.
25. Magliozzi, R., S. Columba-Cabezas, B. Serafini, and F. Aloisi. 2004. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148: 11-24.
26. Roggero, E., E. Zucca, C. Mainetti, F. Bertoni, C. Valsangiacomo, E. Pedrinis, B. Borisch, J. C. Piffaretti, F. Cavalli, and P. G. Isaacson. 2000. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum. Pathol. 31: 263-268.
27. Narayan, K., D. Dail, L. Li, D. Cadavid, S. Amrute, P. Fitzgerald-Bocarsly, and A. R. Pachner. 2005. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann. Neurol. 57: 813-823.
28. Hjelmstrom, P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J. Leukocyte Biol. 69: 331-339, 2001. Review.
29. Huang, X., M. Di Liberto, A. F. Cunningham, L. Kang, S. Cheng, S. Ely, H. C. Liou, I. C. Maclennan, and S. Chen-Kiang. 2004. Homeostatic cell-cycle control by BLyS: induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc. Natl. Acad. Sci. USA 101: 17789-17794.
30. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
31. Yan M., S. A. Marsters, I. S. Grewal, H. Wang, A. Ashkenazi, and V. M. Dixit. 2000. Nat. Immunol. 1: 37.
32. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat. Immunol. 1: 37-41.
33. Vora, K. A., L. C. Wang, S. P. Rao, Z. Y. Liu, G. R. Majeau, A. H. Cutler, P. S. Hochman, M. L. Scott, and S. L. Kalled. 2003. Germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J. Immunol. 171: 547.
34. Rahman, Z. S., S. P. Rao, S. L. Kalled, and T. Manser. 2003. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J. Exp. Med. 198: 1157-1169.
35. Ng, L. G., A. P. Sutherland, R. Newton, F. Qian, T. G. Cachero, M. L. Scott, J. S. Thompson, J. Wheway, T. Chtanova, J. Groom, et al. 2004. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells J. Immunol. 173: 807-817.
36. Zhang, X., C. S. Park, S. O. Yoon, L. Li, Y. M. Hsu, C. Ambrose, and Y. S. Choi. 2005. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int. Immunol. 17: 779-788.
37. Thompson, J. S., S. A. Bixler, F. Qian, K. Vora, M. L. Scott, T. G. Cachero, C. Hession, and P. Schneider. 2001. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
38. Hla, T., and K. Neilson. 1992. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89: 7384-7388.
39. Wun, T., H. McKnight, and J. M. Tuscano. 2004. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res. 28: 179-190.
40. Potter, M., J. Wax, and G. M. Jones. 1997. Indomethacin is a potent inhibitor of pristane and plastic induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. Blood 90: 260-269.
41. Soslow, R. A., A. J. Dannenberg, D. Rush, B. M. Woerner, K. N. Khan, J. Masferrer, and A. T. Koki. 2000. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645.
42. Phipps, R. P., E. Ryan, and S. H. Bernstein. 2004. Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma? Leuk. Res. 28: 109-111. Review.
43. Leng, J., C. Han, A. J. Demetris, G. K. Michalopoulos, and T. Wu. 2003. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38: 756-768.
44. Ferrandez, A., S. Prescott, and R. W. Burt. 2003. COX-2 and colorectal cancer. Curr. Pharm. Des. 9: 2229-2251. Review.
45. Arun, B., and P. Goss. 2004. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol. 31: 22-29. Review.
46. 2 production in response to pro-inflammatory signals. Eur. J. Immunol. 29: 3793-3803.
47. Ryan, E. P., S. J. Pollock, T. I. Murant, S. H. Bernstein, R. E. Felgar, and R. P. Phipps. 2005. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J. Immunol. 174: 2619-2626.
48. Mongini, P. K. A., C. A. Blessinger, P. F. Highet, and J. K. Inman. 1992. Membrane IgM-mediated signaling of human B cells. Effect of increased ligand binding site valency on the affinity and concentration requirements for inducing diverse stages of activation. J. Immunol. 148: 3892-3901.
49. karpusas, M., T. G. Cachero, F. Qian, A. Boriack-Sjodin, C. Mullen, K. Strauch, Y. M. Hsu, and S. L. Kalled. 2002. Crystal structure, of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J. Mol. Biol. 315: 1145-1154.
50. Yu, G., T. Boone, J. Delaney, N. Hawkins, M. Kelley, M. Ramakrishnan, S. McCabe, W. R. Qiu, M. Kornuc, X. Z. Xia, et al. 2000. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1: 252-256.
51. Mongini, P. K., A. E. Jackson, S. Tolani, R. J. Fattah, and J. K. Inman. 2003. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. J. Immunol. 171: 5244-5254.
52. Thiele, D. L., and P. E. Lipsky. 1992. Spectrum of toxicities of ami no acid methyl esters for myeloid cells is determined by distinct metabolic pathways. Blood 79: 964-971.
53. Avery, D. T., S. L. Kalled, J. I. Ellyard, C. Ambrose, S. A. Bixler, M. Thien, R. Brink, F. Mackay, P. D. Hodgkin, and S. G. Tangye. 2003. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112: 286-297.
54. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
55. Hasbold, J., A. V. Gett, J. S. Rush, E. Deenick, D. Avery, J. Jun, and P. D. Hodgkin. 1999. Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester. Immunol. Cell Biol. 77: 516-522.
56. Amin, A. R., M. Attur, R. N. Patel, G. D. Thakker, P. J. Marshall, J. Rediske, S. A. Stuchin, I. R. Patel, and S. B. Abramson. 1997. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. J. Clin. Invest. 99: 1231-127.
57. Mongini P. K. A., S. Kalled, R. Fattah, and J. Inman. 2004. Human B cell clonal expansion is synergistically augmented upon BCR coligation with CD21 in the presence of IL-4 and BAFF. FASEB J. Meeting Abstracts: A464.
58. Dumitriu, I. E., W. Mohr, W. Kolowos, P. Kern, J. R. Kalden, and M. Hermann. 2001. 5,6-carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples. Anal. Biochem. 299: 247-252.
59. Renno, T., A. Attinger, S. Locatelli, T. Bakker, S. Vacheron, and H. R. MacDonald. 1999. Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J. Immunol. 162: 6312-635.
60. Day, E. S., T. G. Cachero, F. Qian, Y. Sun, D. Wen, M. Pelletier, Y. M. Hsu, and A. Whitty. 2005. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44: 1919-1931.
61. Inoue, Y., T. Otsuka, H. Niiro, S. Nagano, Y. Arinobu, E. Ogami, M. Akahoshi, K. Miyake, I. Ninomiya, S. Shimizu, et al. 2004. Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes. J. Immunol. 172: 2147-2154.
62. Fitzpatrick, F. A., R. Aguirre, J. E. Pike, and F. H. Lincoln. 1980. The stability of 13,14-dihydro-15 keto-PGE2. Prostaglandins 19: 917-931.
63. Granstrom, E., M. Hamberg, G. Hansson, and H. Kindahl. 1980. Chemical instability of 15-keto-13,14-dihydro-PGE2: the reason for low assay reliability. Prostaglandins 19: 933-957.
64. Brown, D. M., and R. P. Phipps. 1995. Characterization and regulation of prostaglandin E2 receptors on normal and malignant murine B lymphocytes. Cell Immunol. 161: 79-87.
65. Xu, L., L. Zhang, Y. Yi, H. K. Kang, and S. K. Datta. 2004. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10: 411-415.
66. Capone, M. L., S. Tacconelli, M. G. Sciulli, P. Patrignani. 2003. Clinical pharmacology of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol. 16: 49-58. Review.
67. Corcoran, C. A., Q. He, Y. Huang, and M. S. Sheikh. 2005. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 24: 1634-1640.
68. Trifan, O. C., R. M. Smith, B. D. Thompson, and T. Hla. 1999. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J. Biol. Chem. 274: 34141-34147.
69. Mnich, S. J., A. W. Veenhuizen, J. B. Monahan, K. C. Sheehan, K. R. Lynch, P. C. Isakson, and J. P. Portanova. 1995. Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. J. Immunol. 155: 4437-4444.
70. Lin, M. T., R. C. Lee, P. C. Yang, F. M. Ho, and M. L. Kuo. 2001. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 276: 48997-49002.
71. Ingold, K., A. Zumsteg, A. Tardivel, B. Huard, Q. G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al. 2005. Identification of proteoglycans as the APRIL-specific binding partners. J. Exp. Med. 201: 1375-1383.
72. Roschke, V., S. Sosnovtseva, C. D. Ward, J. S. Hong, R. Smith, V. Albert, W. Stohl, K. P. Baker, S. Ullrich, B. Nardelli, et al. 2002. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J. Immunol. 169: 4314-4321.
73. He, B., A. Chadburn, E. Jou, E. J. Schattner, D. M. Knowlesk, and A. Cerutti, A. 2004. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. 172: 3268-3279.
74. Moreaux, J., E. Legouffe E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J. F. Rossi, B. Klein, and K. Tarte. 2004. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157.
75. Xia, X. Z., J. Treanor, G. Senaldi, S. D. Khare, T. Boone, M. Kelley, L. E. Thiell, A. Colombero, I. Solovyev, F. Lee, et al. 2000. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J. Exp. Med. 192: 137-143.
76. Hatzoglou, A., J. Roussel, M. F. Bourgeade, E. Rogier, C. Madry, J. Inoue, O. Devergne, and A. Tsapis. 2000. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF)1, TRAF2, and TRAF3 and activates NF-κB, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 165: 1322-1330.
77. von Bulow, G. U., and R. J. Bram. 1997. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278: 138-141.
78. D'Acquisto, F., T. Iuvone, L. Rombola, L. Sautebin, M. Di Rosa, and R. Carnuccio. 1997. Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett. 418: 175-178.
79. Kojima, M., T. Morisaki, K. Izuhara, A. Uchiyama, Y. Matsunari, M. Katano, and M. Tanaka. 2000. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation. Oncogene 19: 1225-1231.
80. Iniguez, M. A., S. Martinez-Martinez, C. Punzon, J. J. Redondo, and M. Fresno. 2000. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J. Biol. Chem. 275: 23627-23635.
81. Garrone, P., L. Galibert, F. Rousset, S. M. Fu, and J. Banchereau. 1994. Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen. J. Immunol. 152: 4282-4290.
82. Simkin, N. J., D. F. Jelinek, and P. E. Lipsky. 1987. Inhibition of human B cell responsiveness by prostaglandin E2. J. Immunol. 138: 1074-1081.
83. Garrone, P., and J. Banchereau. 1993. Agonistic and antagonistic effects of cholera toxin on human B lymphocyte proliferation. Mol. Immunol. 30: 627-635.
84. Roper, R. L., D. H. Conrad, D. M. Brown, G. L. Warner, and R. P. Phipps. 1990. Prostaglandin E2 promotes IL-4-induced IgE and IgG1 synthesis. J. Immunol. 145: 2644-2651.
85. Ohmori, H., M. Hikida, and T. Takai. 1990. Prostaglandin E2 as a selective stimulator of antigen-specific IgE response in murine lymphocytes. Eur. J. Immunol. 20: 2499-2503.
86. Fedyk, E. R., and R. P. Phipps. 1996. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc. Natl. Acad. Sci. USA 93: 10978-10983.
87. Roper, R. L. 2002. Prostaglandin E2 and cAMP promote B lymphocyte class switching to IgG1. Immunol. Lett. 84: 191-198.
88. Hodgkin, P. D., J. H. Ue, and A. B. Lyons. 1996. B cell differentiation and isotype switching is related to division cycle number. J. Exp. Med. 184: 277-281.
89. Castigli, E., S. Scott, F. Dedeoglu, P. Bryce, H. Jabara, A. K. Bhan, E. Mizoguchi, and R. S. Geha. 2004. Impaired IgA class switching in APRIL-deficient mice. Proc. Natl. Acad. Sci. USA 101: 3903-398.
90. Stein J. V., M. Lopez-Fraga, F. A. Elustondo, C. E. Carvalho-Pinto, D. Rodriguez, R. Gomez-Caro, J. De long, C. Martinez-A, J. P. Medema, and M. Hahne. 2002. APRIL modulates B and T cell immunity. J. Clin. Invest. 109: 1587-1598.
91. Milich, D. R., and A. McLachlan. 1986. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234: 1398-1401.
92. Macpherson, A. J., D. Gatto, E. Sainsbury, G. R. Harriman, H. Hengartner, and R. M. Zinkemagel. 2000. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288: 2222-226.
93. von Bulow, G. U., and R. J. Bram. 1997. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278: 138-141.
94. Castigli, E., S. A. Wilson, S. Scott, F. Dedeoglu, S. Xu, K. P. Lam, R. J. Bram, H. Jabara, and R. S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201: 35-39.
95. Yan, M., H. Wang, B. Chan, M. Roose-Girma, S. Erickson, T. Baker, D. Tumas, I. S. Grewal, and V. M. Dixit. 2001. Activation and accumulation of B cells in TAGI-deficient mice. Nat. Immunol. 2: 638-643.
96. Seshasayee, D., P. Valdez, M. Yan, V. M. Dixit, D. Tumas, and I. S. Grewal. 2003. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
97. O'Connor, B. P.; V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L. L. Lin, G. T. Mantchev, R. J. Bram, and R. J. Noelle. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med 199: 91-98.
98. Moreaux, J. E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J. F. Rossi, B. Klein, and K. Tarte. 2004. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157.
99. Yang, T., K. M. Kozopas, and R. W. Craig. 1995. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J. Cell Biol. 128: 1173-1184.
100. Opferman, J. T., A. Letai, C. Beard, M. D. Sorcinelli, C. C. Ong, and S. J. Korsmeyer. 2003. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: 671-676.
101. Cuconati, A., C. Mukherjee, D. Perez, and E. White. 2003. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 17: 2922-2932.
102. Shu, H. B., and H. Johnson. 2000. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc. Natl. Acad. Sci. USA 97: 9156-9161.
103. Bishop, G. A., B. S. Hostager, and K. D. Brown. 2002. Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J. Leukocyte Biol. 72: 19-23.
104. Lomo, J., H. K. Blomhoff, S. E. Jacobsen, S. Krajewski, J. C. Reed, and E. B. Smeland. 1997. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood 89: 4415-4424.
105. Kitada, S., J. M. Zapata, M. Andreeff, and J. C. Reed. 1999. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 106: 995-1004.
106. Krajewski, S., S. Bodrug, M. Krajewska, A. Shabaik, R. Gascoyne, K. Berean, and J. C. Reed. 1995. Immunohistochemical analysis of Mcl-1 protein in human tissues: differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. American J. Pathol. 146: 1309-1319.
107. Shao, J., H. Sheng, H. Inoue, J. D. Morrow, and R. N. DuBois. 2000. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275: 33951-33956.
108. Craig, R. W. 2002. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454.
109. Michels J., P. W. Johnson, and G. Packham. 2005. Mcl-1. Int. J. Biochem. Cell Biol. 37: 267-271. Review.
110. Barrios-Rodiles, M., and K. Chadee. 1998. Novel regulation of cyclooxygenase-2 expression and prostaglandin E2 production by IFN-γ in human macrophages. J. Immunol. 161: 2441-248.
111. Ohata, J., N. J. Zvaifler, M. Nishio, D. L. Boyle, S. L. Kalled, D. A. Carson, and T. J. Kipps. 2005. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J. Immunol. 174: 864-870.
112. Tan, S. M., D. Xu, V. Roschke, J. W. Perry, D. G. Arkfeld, G. R. Ehresmann, T. S. Migone, D. M. Hubert, and W. Stohl. 2003. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 48: 982-992.
113. Szodoray, P., S. Jellestad, M. O. Teague, and R. Jonsson. 2003. Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren's syndrome. Lab. Invest. 83: 357-365.
114. Groom, J., S. L. Kalled, A. H. Cutler, C. Olson, S. A. Woodcock, P. Schneider, J. Tschopp, T. G. Cachera, M. Batten, J. Wheway, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109: 59-68.
115. Krumbholz, M., D. Theil, T. Derfuss, A. Rosenwald, F. Schrader, C. M. Monoranu, S. L. Kalled, D. M. Hess, B. Serafini, F. Aloisi, et al. 2005. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201: 195-200.
116. 2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs. 63: 31-36.
117. 2 in joint fluid in rheumatoid arthritis patients using gas chromatography/selected ion monitoring. Prostaglandins Other Lipid Mediat. 58: 179-186.
118. Tishler, M., I. Yaron, A. Raz, F. A. Meyer, and M. Yaron. 1996. Salivary eicosanoid concentration in patients with Sjogren's syndrome. Ann. Rheum. Dis. 55: 202-204.